Vaxxas


Vaxxas is a biotechnology company focused on enhancing the performance of vaccines through its proprietary high-density microarray patch (HD-MAP) technology. The company aims to revolutionize vaccine delivery with needle-free, easy-to-administer, and thermostable solutions, targeting infectious diseases and oncology. With a strong pipeline of clinical trials and collaborations with global organizations, Vaxxas is advancing toward commercialization of its innovative vaccine platform.

Industries

biotechnology
health-care
medical-device

Nr. of Employees

medium (51-250)

Vaxxas

Brisbane, Queensland, Australia, Oceania


Products

High-density microarray patch vaccine delivery platform

A vaccine delivery platform consisting of a small patch with thousands of microscopic projections coated with dried vaccine, integrated into a single-use applicator for short-duration skin application to deliver antigen to skin-resident immune cells.


Services

GMP manufacturing of vaccine-coated microarray patches

Aseptic production and batch manufacturing of combination patch-and-applicator products in GMP-capable facilities to support clinical supply and scale-up.

Clinical development and trial execution for patch-delivered vaccines

Design, conduct and support of early-stage clinical trials (safety, tolerability, immunogenicity) for vaccines delivered via microarray patches.

CMC, formulation and analytical development

Formulation development for dried vaccine coatings, stability testing at elevated temperatures, and analytical method development to support regulatory submissions.

Device engineering and process transfer

Design and engineering of applicator devices, automation and transfer of prototype processes into scalable manufacturing lines.

Licensing and partnership programs

Commercial licensing of the patch platform to pharmaceutical companies and collaboration on co-development programs; in-licensing of vaccine antigens for platform integration.

Expertise Areas

  • Microarray patch vaccine delivery
  • Vaccine formulation and thermostability
  • Clinical trial management for early‑stage vaccine studies
  • GMP biomanufacturing and aseptic processing
  • Show More (6)

Key Technologies

  • High-density microarray patches (microprojection patches)
  • Dry-coating / crystalline vaccine formulations
  • Thermostable vaccine formulations (ambient stability testing)
  • Single-use applicator devices for transdermal delivery
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.